MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Anavex Life Sciences Corp

Închisă

SectorSănătate

11.24 3.31

Rezumat

Modificarea prețului

24h

Curent

Minim

10.69

Maxim

11.28

Indicatori cheie

By Trading Economics

Venit

915K

-11M

Angajați

42

EBITDA

106K

-12M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+162.19% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

201M

928M

Deschiderea anterioară

7.93

Închiderea anterioară

11.24

Sentimentul știrilor

By Acuity

17%

83%

26 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 iul. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 iul. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 iul. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 iul. 2025, 22:38 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 iul. 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 iul. 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Cuts Top End of 2025 Production Guidance

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Production Recovery Underway in Cooper Basin

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Free Cash Flow From Operations US$620 Million

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 iul. 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 iul. 2025, 22:33 UTC

Market Talk
Câștiguri

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 iul. 2025, 22:28 UTC

Market Talk
Câștiguri

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Market Talk Roundup: Latest on U.S. Politics

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparație

Modificare preț

Anavex Life Sciences Corp Așteptări

Obiectiv de preț

By TipRanks

162.19% sus

Prognoză pe 12 luni

Medie 28.5 USD  162.19%

Maxim 42 USD

Minim 15 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAnavex Life Sciences Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.275 / 9.312Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

26 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.